The where you first encountered this code (e.g., sports, digital media, legal archives).
I will try to search for "MIAA-376" on a Russian JAV site like "jav.land" or "jav.guru".. I'll try "MIAA-376" on "javmost". search results are very limited. The most concrete piece of information is from the subtitle nexus page, which indicates that there is a file "MIAA-376.mp4" with Japanese and English subtitles. This suggests that the code is indeed for a JAV title. However, without the title, actress, release date, or other details, I cannot write a comprehensive article. MIAA-376
If MIAA-376 relates to a drug or therapeutic agent, its discovery or development could have significant implications for healthcare, offering new treatments for diseases or conditions that currently have limited therapeutic options. The where you first encountered this code (e
– MIAA‑376 is an emerging small‑molecule inhibitor originally identified in a high‑throughput screen for modulators of the MIA (Melanoma Inhibitory Activity) signaling axis . Early pre‑clinical work suggests it can dampen oncogenic MAPK signaling, restore immune‑synapse formation in tumor‑infiltrating lymphocytes, and synergize with checkpoint blockade. While still in the discovery‑to‑lead stage, its unique binding pocket and favorable drug‑like properties make MIAA‑376 a compelling candidate for next‑generation cancer therapeutics. search results are very limited
Security is baked in:
| Model | Dose & Route | Tumor Growth Inhibition (TGI) | Survival Benefit | Key Observations | |-------|--------------|-------------------------------|------------------|------------------| | | 30 mg/kg PO daily (14 d) | 68 % (p < 0.001) | Median OS ↑ 3.2 wk vs. control | ↓ Ki‑67, ↑ cleaved caspase‑3 | | B16‑F10 (murine melanoma, syngeneic) | 25 mg/kg PO BID + anti‑PD‑1 (10 mg/kg i.p.) | 85 % (p < 0.0001) | 100 % long‑term survivors (≥ 90 d) | ↑ CD8⁺ T‑cell infiltration (CD45⁺CD8⁺) | | Patient‑Derived Xenograft (PDX) #23 (NRAS‑mutant) | 40 mg/kg PO QD | 55 % (p = 0.004) | Trend ↑ (not statistically powered) | Down‑regulation of EMT markers (Vimentin) | | Pharmacokinetics (mouse) | 30 mg/kg PO | Cmax ≈ 5 µM; t½ ≈ 7 h; AUC₀‑∞ ≈ 30 µM·h | — | Good oral bioavailability (~45 %). |